In a landmark study, Johnson & Johnson has announced that ERLEADA (apalutamide) significantly reduces the risk of death by 23% at 24 months compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer (mCSPC).

ERLEADA shows 23% survival benefit over enzalutamide in prostate cancer study – PharmaTimes